Determination of avibactam and ceftazidime in human plasma samples by LC-MS

Bioanalysis

Volumn 7, Issue 12, 2015, Pages 1423-1434

  Sillén, Henrik ^a   Mitchell, Richard ^b   Sleigh, Rebecca ^c   Mainwaring, Guy ^d   Catton, Katherine ^b   Houghton, Richard ^e   Glendining, Karen ^d  

^a ASTRAZENECA R AND D   (Sweden)

^b Bioanalytical Department   (United Kingdom)

^c LGC   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e Quotient Bioresearch Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; CEFTAZIDIME; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; HUMAN; LIQUID CHROMATOGRAPH; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MASS SPECTROMETRY; MEASUREMENT ACCURACY; PLASMA; RELIABILITY; VALIDATION STUDY; BLOOD; CHEMISTRY; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES; QUALITY CONTROL; STANDARDS; TANDEM MASS SPECTROMETRY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BLOOD CHEMICAL ANALYSIS; CEFTAZIDIME; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; QUALITY CONTROL; TANDEM MASS SPECTROMETRY;

EID: 84937064997     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.76     Document Type: Article

References (35)

1. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 362 (19), 1804-1813 (2010).
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
3. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J. Intern. Med. 27(2), 128-142 (2012).
4. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 86(3), 250-259 (2011).
5. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios P T, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25(4), 682-707 (2012).
6. Magiorakos A P, Suetens C, Monnet DL, Gagliotti C, Heuer OE. The rise of carbapenem resistance in Europe: just the tip of the iceberg? Antimicrob. Resist. Infect. Control 2(1), 6 (2013).
7. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet. Infect. Dis. 13(9), 785-796 (2013).
8. Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70(3), 313-333 (2010).
9. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J. Antimicrob. Chemother. 62(5), 1053-1056 (2008).
10. Stachyra T, Levasseur P, Pechereau MC et al. In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64(2), 326-329 (2009).
11. Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 39(1), 86-89 (2012).
12. Lagace-Wiens PR, Tailor F, Simner P et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob. Agents Chemother. 55(5), 2434-2437 (2011).
13. Levasseur P, Girard AM, Claudon M et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 56(3), 1606-1608 (2012).
14. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J. Antimicrob. Chemother. 65(11), 2376-2381 (2010).
15. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob. Agents Chemother. 56(9), 4779-4785 (2012).
16. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55(1), 390-394 (2011).
17. Coleman K, Levasseur P, Girard AM et al. Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fber pharmacodynamic model. Antimicrob. Agents Chemother. 58(6), 3366-3372 (2014).
18. Zhanel GG, Lawson CD, Adam H et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs 73(2), 159-177 (2013).
19. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the effcacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J. Antimicrob. Chemother. 68(5), 1183-1192 (2013).
20. Vazquez JA, Gonzalez Patzan LD, Stricklin D et al. Effcacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 28 (12), 1921-1931 (2012).
21. Clinical Trials Database: NCT01726023. www.clinicaltrials.gov
22. Clinical Trials Database: NCT01499290. www.clinicaltrials.gov
23. Clinical Trials Database: NCT01500239. www.clinicaltrials.gov
24. Clinical Trials Database: NCT01595438. www.clinicaltrials.gov
25. Clinical Trials Database: NCT01599806. www.clinicaltrials.gov
26. Clinical Trials Database: NCT01808092. www.clinicaltrials.gov
27. Clinical Trials Database: NCT01644643. www.clinicaltrials.gov
28. FDA News Release. FDA Approves New Antibacterial Drug Avycaz. www.fda.gov
29. Guitton J, Laffont A, Bruzeau J, Rochet-Mingret L, Bonnefoy M, Bureau J. Determination of ceftazidime in plasma using high-performance liquid chromatography and electrochemical detection. Application for individualizing dosage regimens in elderly patients. J. Chromatogr. B. Biomed. Sci. Appl. 719(1-2), 151-157 (1998).
30. Zhang J, Chen X, Dai X et al. Simultaneous determination of ceftazidime and tazobactam in human plasma with sequential positive and negative ionization liquid chromatography-tandem mass spectrometric detection. Chin. J. Pharm. Anal. 32, 20-25 (2012).
31. US FDA. Guidance for Industry, Bioanalytical Method Validation. www.fda.gov
32. Vishwanathan K, Mair S, Gupta A et al. Assessment of the mass balance recovery and metabolite profle of avibactam in humans and in vitro drug-drug interaction potential. Drug Metab. Dispos. 42(5), 932-942 (2014).
33. Deshpando DA, Baheti KG, Chatterjee NR. Degradation of b-lactam antibiotics. Curr. Sci. 87(12), 1684-1695 (2004).
34. Das S, Armstrong J, Mathews D, Li J, Edeki T. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. J. Clin. Pharmacol. 54(3), 331-340 (2014).
35. Sillen H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 878(25), 2299-2306 (2010).